Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection
- 1 January 2008
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 82 (1), 115-125
- https://doi.org/10.1128/jvi.00927-07
Abstract
Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency virus type 1 (HIV-1) envelope g41 cluster II membrane proximal external region (MPER) broadly neutralize HIV-1 primary isolates. However, these antibody specificities are rare, are not induced by Env immunization or HIV-1 infection, and are polyspecific and also react with lipids such as cardiolipin or phosphatidylserine. To probe MPER anti-gp41 antibodies that are produced in HIV-1 infection, we have made two novel murine MAbs, 5A9 and 13H11, against HIV-1 gp41 envelope that partially cross-blocked 2F5 MAb binding to Env but did not neutralize HIV-1 primary isolates or bind host lipids. Competitive inhibition assays using labeled 13H11 MAb and HIV-1-positive patient plasma samples demonstrated that cluster II 13H11-blocking plasma antibodies were made in 83% of chronically HIV-1 infected patients and were acquired between 5 to 10 weeks after acute HIV-1 infection. Both the mouse 13H11 MAb and the three prototypic cluster II human MAbs (98-6, 126-6, and 167-D) blocked 2F5 binding to gp41 epitopes to variable degrees; the combination of 98-6 and 13H11 completely blocked 2F5 binding. These data provide support for the hypothesis that in some patients, B cells make nonneutralizing cluster II antibodies that may mask or otherwise down-modulate B-cell responses to immunogenic regions of gp41 that could be recognized by B cells capable of producing antibodies like 2F5.This publication has 56 references indexed in Scilit:
- Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion stateVaccine, 2007
- Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C InfectionJournal of Virology, 2007
- Monoclonal Antibodies to Phosphatidylinositol Phosphate Neutralize Human Immunodeficiency Virus Type 1: Role of Phosphate-Binding SubsitesJournal of Virology, 2007
- Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern AfricaJournal of Virology, 2006
- Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentrationBiochemical and Biophysical Research Communications, 2006
- A Nonneutralizing Anti-HIV Type 1 Antibody Turns into a Broad Neutralizing Antibody When Expressed on the Surface of HIV Type 1-Susceptible Cells. II. Inhibition of HIV Type 1 Captured and Transferred by DC-SIGNAIDS Research and Human Retroviruses, 2006
- Antibody‐Mediated Regulation of the Immune ResponseScandinavian Journal of Immunology, 2006
- Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesExpert Review of Vaccines, 2006
- Antibody neutralization and escape by HIV-1Nature, 2003
- Search for Epitope-Specific Antibody Responses to the Human Immunodeficiency Virus (HIV-1) Envelope Glycoproteins Signifying Resistance to Disease DevelopmentAIDS Research and Human Retroviruses, 1990